OLMA Olema Pharmaceuticals, Inc.
$7.04▲ +6.34%
Healthcare
Other
Volume 2.19M
Avg Volume (10D) 1.56M
Key Metrics & Fundamentals
Market Cap
$615.98M
P/E Ratio
–
Div Yield
0.00%
52W Range
6.24 - 36.26
% vs 50 MA
-22.28%
% vs 200 MA
-50.92%
RSI-14
38.4
MACD Histogram
+0.0500
Beta (1Y vs SPY)
0.44
Free Cash Flow
-$46.12M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$67.08M
COGS
–
Operating Exp
$67.18M
Operating Income
-$67.18M
EBIT
-$67.18M
Pretax Income
-$63.20M
Net Income
-$63.20M
EPS (Diluted)
-0.61
Price & Volume History
Loading chart…
Recent News
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
Zacks · Oct 19, 2026 8:00 AM ET
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Zacks · Oct 16, 2026 8:45 AM ET
SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight
PR Newswire · Oct 5, 2026 10:31 AM ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 4:30 PM ET
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
InvestorsHub · Sep 14, 2026 8:10 AM ET
Top Premarket Decliners
MT Newswires · Sep 14, 2026 7:44 AM ET
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump
Investing.com · Sep 14, 2026 7:41 AM ET
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 2, 2026 4:30 PM ET
Olema Oncology to Participate in Upcoming Investor Conferences
GlobeNewswire · Aug 31, 2026 4:30 PM ET
Olema Pharmaceuticals Names Jason O'Byrne CFO
MT Newswires · Aug 13, 2026 8:48 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See OLMA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.